Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hallucinations Clear all
Terminated Not applicable Interventional Results available

The Use of Transcranial Electrical Stimulation for Hallucinations

NCT02715765
View directory record Official record
Conditions
Schizophrenia
Interventions
Transcranial Direct Current Stimulation, Transcranial Random Noise Stimulation, Transcranial Sham Stimulation
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 25, 2020 · Synced Sep 10, 2026, 4:41 PM EDT
Not yet recruiting Not applicable Interventional

LIFU Effects & Outcomes: Mechanisms Evaluating Striatal Systems Imaging (LEO MESSI)

NCT07710989
View directory record Official record
Conditions
Schizophrenia, Auditory Hallucinations
Interventions
LIFU
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Recruiting Phase 2Phase 3 Interventional

ACP-204 in Adults With Alzheimer's Disease Psychosis

NCT06159673
View directory record Official record
Conditions
Alzheimer's Disease Psychosis
Interventions
ACP-204, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
55 Years to 95 Years
Enrollment
1,074 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
47
States / cities
Chandler, Arizona • Scottsdale, Arizona • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Enrolling by invitation Phase 3 Interventional

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

NCT06194799
View directory record Official record
Conditions
Alzheimer's Disease Psychosis
Interventions
ACP-204
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
55 Years to 95 Years
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
21
States / cities
Costa Mesa, California • Fresno, California • Garden Grove, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Recruiting Not applicable Interventional

Using Transcranial Magnetic Stimulation (TMS) to Understand Hallucinations in Schizophrenia

NCT05343598
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS), Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Terminated Not applicable Interventional Results available

Boost rTMS for Auditory Verbal Hallucinations

NCT03544333
View directory record Official record
Conditions
Schizophrenia, Auditory Hallucination
Interventions
transcranial magnetic stimulation
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Not applicable Interventional

Transcranial Direct-current Stimulation (tDCS) in Treatment Refractory Auditory Hallucinations

NCT03485131
View directory record Official record
Conditions
Auditory Hallucination, Schizophrenia
Interventions
Transcranial direct-current stimulation (tDCS), Placebo
Device
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Results available

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

NCT03325556
View directory record Official record
Conditions
Dementia-related Psychosis
Interventions
Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
27
States / cities
Costa Mesa, California • Fullerton, California • Aventura, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Sep 10, 2026, 4:41 PM EDT
Recruiting Phase 4 Interventional

Comparing Antipsychotic Medications in LBD Over Time

NCT05590637
View directory record Official record
Conditions
Parkinson's Disease Psychosis, Dementia With Lewy Bodies
Interventions
Pimavanserin, Quetiapine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 4 Interventional

Donepezil to Treat Dementia in Parkinson's Disease

NCT00030979
View directory record Official record
Conditions
Parkinson Disease
Interventions
Donepezil
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 10, 2026, 4:41 PM EDT
Enrolling by invitation Phase 2 Interventional

An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

NCT07459660
View directory record Official record
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
ML-007C-MA
Drug
Lead sponsor
MapLight Therapeutics
Industry
Eligibility
55 Years to 91 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Anaheim, California • Doral, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Results available

Pain Medicine for Wound Care Procedures

NCT00701909
View directory record Official record
Conditions
Wound Care, Pain Intensity, Hyperalgesia, Nausea, Vomiting, Hallucinations
Interventions
Morphine plus Ketamine, Morphine plus Saline (placebo)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 2 Interventional

Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug

NCT00087542
View directory record Official record
Conditions
Hallucinations, Psychoses, Parkinson's Disease
Interventions
ACP-103
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
0 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
13
States / cities
Fountain Valley, California • Sunnyvale, California • Danbury, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2005 · Synced Sep 10, 2026, 4:41 PM EDT
Completed No phase listed Observational

Perception in Parkinson's Disease

NCT05483036
View directory record Official record
Conditions
Parkinson's Disease, Perception, Visual Hallucination
Interventions
Not listed
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
40 Years to 110 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Repetitive Transcranial Magnetic Stimulation on Resting State Brain Activity in Schizophrenia

NCT01620086
View directory record Official record
Conditions
Schizophrenia
Interventions
Active Repetitive Transcranial Magnetic Stimulation 1 Hz, Active Repetitive Transcranial Magnetic Stimulation 10 Hz, Active control site Repetitive Transcranial Magnetic Stimulation at 1Hz, Sham control site Repetitive Transcranial Magnetic Stimulation, Active control site Repetitive Transcranial Magnetic Stimulation at 10 Hz
Device
Lead sponsor
University of Arkansas
Other
Eligibility
21 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2016 · Synced Sep 10, 2026, 4:41 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

DecNef for AVH in Schizophrenia

NCT07779226
View directory record Official record
Conditions
Schizophrenia Disorder, Schizoaffecitve Disorder
Interventions
Decoded Neurofeedback
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Withdrawn Not applicable Interventional

Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia

NCT02661347
View directory record Official record
Conditions
Schizophrenia, Schizophreniform, Schizoaffective Disorder, Psychosis Not Otherwise Specified (NOS)
Interventions
Risperidone, tDCS
Drug · Device
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 10, 2026, 4:41 PM EDT
Terminated Not applicable Interventional Results available

Auditory Control Enhancement (ACE) in Schizophrenia

NCT06155695
View directory record Official record
Conditions
Auditory Hallucinations
Interventions
Transcranial Direct Current Stimulation (tDCS), Auditory Cognitive Control Training (ACCT)
Device · Behavioral
Lead sponsor
Brian A Coffman, PhD
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Not yet recruiting Not applicable Interventional

Testing a Peer-Support Group for Veterans Who Hear Voices

NCT07555275
View directory record Official record
Conditions
Psychotic Disorders, Hallucinations, Auditory, Social Isolation
Interventions
Veteran Voices and Visions (VVV), Wellness Recovery Action Planning (WRAP)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
2
States / cities
West Los Angeles, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Recruiting Early Phase 1 Interventional

Toward a Computationally-Informed, Personalized Treatment for Hallucinations

NCT04366518
View directory record Official record
Conditions
Hallucinations, Auditory, Psychosis
Interventions
Rivastigmine Transdermal System, Scopolamine, Placebo Patch
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 10, 2026, 4:41 PM EDT
Terminated Phase 2 Interventional

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

NCT02871427
View directory record Official record
Conditions
Lewy Body Dementia, Dementia With Lewy Bodies, Parkinson's Disease Dementia, Visual Hallucinations, REM Sleep Behavior Disorder
Interventions
Nelotanserin
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
19
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Boca Raton, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Quantifying Abnormalities in Cortical Activation Associated With Auditory Hallucinations Using Functional Magnetic Resonance Imaging

NCT00288340
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Hallucinations
Interventions
functional magnetic resonance imaging
Device
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy of PEAR-004 in Schizophrenia

NCT03751280
View directory record Official record
Conditions
Schizophrenia
Interventions
PEAR-004, Sham
Device
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Garden Grove, California • Oakland, California • Torrance, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 10, 2026, 4:41 PM EDT
Terminated Not applicable Interventional Results available

An Extension Protocol for Patients Who Previously Completed the TMS Pilot Study

NCT05526833
View directory record Official record
Conditions
Schizophrenia and Related Disorders
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
Columbia University
Other
Eligibility
22 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Sep 10, 2026, 4:41 PM EDT